We characterized the effect of MORAb-202, which is a novel ADC that comprises the anti-FOLR1 antibody conjugated to eribulin via a cleavable linker, on breast cancer and NSCLC cell lines. Here, FOLR1 is linked to non-small cell lung carcinoma.